← All trials
NCT04735861
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 1, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Dec 31, 2023
- First posted
- Feb 3, 2021
- Last posted
- Oct 14, 2021
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Wuhan UniversityCollaborator
- Zhengzhou UniversityCollaborator
- Shandong UniversityCollaborator
- Henan Medical UniversityCollaborator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Shengjing HospitalCollaborator
- The First People's Hospital of JingzhouCollaborator
- Wuhan UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Jingzhou Central HospitalCollaborator
- Central South UniversityCollaborator
- Huazhong University of Science and TechnologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.